mRNA

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

mRNA vaccines
#Biologics #Biotechnology #Cell and gene therapy #Contract development and manufacturing organisations #Covid-19 #mRNA #Vaccines

Preparing for new-era drug modalities with technology 

Listen to this article on the DDW podcast: Samsung Biologics’ Senior Vice President, James Park, explores the opportunities emerging for CDMOs to support mRNA developers as they explore new therapeutic areas for patients.  Prior to the pandemic, messenger RNA (mRNA) drug development… Read More

#Exclusive Content

Cancer cells
#Cancer research #mRNA #Wellcome Sanger Institute

Study develops new way of identifying cancer cells  

A new method of separating cancer cells from non-cancer cells has been developed by researchers at the Wellcome Sanger Institute, in a boost for those working to better understand cancer biology using single-cell mRNA sequencing.  The study, published in Communications Biology, improves on existing methods to identify… Read More

#Cancer Research #News

#Clinical development #Immunology / Virology & Vaccines #Infectious diseases #mRNA #Public health

mRNA technology may hold the future for a cytomegalovirus vaccine 

Listen to this article on the DDW podcast: Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. … Read More

#Exclusive Content #Trends & Analysis

RNA strand
#Gene therapy #mRNA #R&D #Research & development #RNA

New solution to boost RNA drug development

Benchling has launched its first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. Following… Read More

#News

#BioNTech #Covid-19 #Immunology / Virology & Vaccines #mRNA

BioNTech to deliver prestigious lecture on mRNA  

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19.   The lecture will be delivered in two halves by Uğur Şahin and Özlem Türeci, co-founders of… Read More

#News

#BioNTech #Covid-19 #CureVac #mRNA #Pfizer

CureVac lawsuit against BioNTech over Covid-19 vaccine technology  

Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.  CureVac has filed the lawsuit in the German Regional Court in… Read More

#News

#Biomarkers #mRNA #Oncology

First patient enrolled in mRNA biomarker study for cancer  

Molecular genetics company Mainz Biomed has enrolled its first patient in an international clinical study assessing the potential combination of gene expression (mRNA) biomarkers with a diagnostic test for colorectal cancer.  The ColoFuture clinical study will see Mainz Biomed integrate a portfolio of novel gene expression (mRNA)… Read More

#News

#Covid-19 #Manufacturing #mRNA

Moderna to set up mRNA vaccine centre in UK 

Pharmaceutical company Moderna is to set-up a manufacturing and research development centre in the UK following an agreement with the government.   The new mRNA Innovation and Technology Centre will develop mRNA vaccines for respiratory diseases including Covid-19 vaccines that can protect against multiple variants. The aim for… Read More

#News

#Covid-19 #mRNA

Collaboration to develop African-owned Covid-19 vaccine 

A collaboration between two biotech companies hopes to pave the way for the development of the first-ever African-owned Covid-19 vaccine.  Afrigen Biologics and the Univercells Group have announced a collaboration to focus on the development of a new mRNA vaccine. The collaboration is being supported by mRNA specialist, eTheRNA, and… Read More

#Covid-19 #News

#Biopharma #Covid-19 #mRNA #Vaccines

mRNA vaccines – how do we keep up with the new kid on the block? 

By Greg Kulnis  – Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Read More

#Exclusive Content

#Biologics / Biotechnology #mRNA #SLAS Europe

The shape of things to come

By DDW Editor-in-Chief Lu Rahman What a difference a year makes. It only feels like a few weeks ago that we were looking forward to SLAS2022 and now we have SLAS Europe on the horizon. How welcome it is to be back in the swing of face-to-face events again compared… Read More

#Exclusive Content

#AI #Biotechnology #Clinical trials #mRNA

Talking tech in 2022

Listen to this article on the DDW Podcast: With Covid-19 taking so much of the drug discovery and development’s focus over the last two years, it has been easy to overlook other areas within the sector that deserve our attention. With Q1 on its way out, Lu Rahman highlights… Read More

#Exclusive Content

#Lipids #mRNA #Research

eTheRNA expands R&D capacity   

mRNA technology discovery and development company, eTheRNA immunotherapies has announced it has relocated its R&D group to a larger site in Belgium.   The company has moved its R&D facility to the Zwijnaarde Science Park in Gent, Belgium, which features a cluster of biotech companies and includes laboratories… Read More

#News

#Antimicrobials #Bioconvergence #Drug development #Immunology / Virology & Vaccines #mRNA

Bioconvergence: Future trends for biomedicine

Dr. Tom Knapman, Director of Strategic Brand at SCIEX, explains how bioconvergent advances will help to drive key health trends in the coming year. As we move into 2022, we will see more and more advances in bioconvergence – biological, physical, and computing technologies inspired by nature. We expect these… Read More

#Exclusive Content #News #Opinion #Trending News #Trends & Analysis